Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.

Therefore, we performed a systematic reviewand pooled analysis of patients with POD24.

因此，我们对POD24患者进行了系统综述和汇总分析。

Twenty-one trials involving 1242 participants were included, assessing the overall response rate (ORR), complete response (CR), duration of response, and progression-free survival. In some trials, we compared pooled response rates between POD24 and non-POD24 populations with the same treatment regimen.

纳入了21项试验，涉及1242名参与者，评估了总缓解率（ORR）、完全缓解（CR）、缓解持续时间及无进展生存期。在一些试验中，我们比较了POD24和非POD24人群中相同治疗方案的综合响应率。

Four trials evaluated chimeric antigen receptor (CAR) T-cell therapy in patients with POD24.

四项试验评估了POD24患者的嵌合抗原受体（CAR）T细胞疗法。

Pooled analysis showed an ORR of 91.2% (95% confidence interval[CI], 83.7-98.7) with significant heterogeneity (P = .0414; I2 = 68.61%) and a CR of 75.7% (95% CI, 55.1-96.4) with significant heterogeneity (P< .0001; I2 = 93.99%).

汇总分析显示总缓解率(ORR)为91.2% (95% 置信区间 [CI], 83.7-98.7)，存在显著异质性 (P = .0414; I2 = 68.61%)，完全缓解(CR)为75.7% (95% CI, 55.1-96.4)，也存在显著异质性 (P< .0001; I2 = 93.99%)。

The specific response rates for different bispecific antibodies in POD24 were pooled analysis, the ORR was 81.6% (95% CI, 75.9-87.3) with no heterogeneity (P = .6958; I2 = 0%), and the CR was 65.7% (95% CI, 57.1-74.3) with moderate heterogeneity (P = .2148; I2 = 34.99%).

在POD24中，不同双特异性抗体的特定反应率进行了汇总分析，总缓解率(ORR)为81.6% (95% CI, 75.9-87.3)，没有异质性 (P = .6958; I2 = 0%)，完全缓解(CR)为65.7% (95% CI, 57.1-74.3)，存在中度异质性 (P = .2148; I2 = 34.99%)。

For anti-CD19 antibody-drug conjugates (ADCs)/monoclonal antibodies (mAbs), the ORR and CR rate for loncastuximab plus rituximab and tafasitamab plus R2 (lenalidomide + rituximab) were 100% and 79.3%, and 87.5% and 43.2%, respectively.

对于抗CD19抗体药物偶联物（ADCs）/单克隆抗体（mAbs），loncastuximab联合利妥昔单抗和tafasitamab联合R2（来那度胺+利妥昔单抗）的客观缓解率（ORR）和完全缓解（CR）率分别为100%和79.3%，以及87.5%和43.2%。

Phosphatidylinositol 3-kinase inhibitors and anti-CD20 mAb-containing regimens were also analyzed in pooled analyses.

磷脂酰肌醇3激酶抑制剂和含抗CD20单克隆抗体的方案也在汇总分析中进行了分析。

Our results demonstrated that anti-CD19 CAR T-cell therapy achieved the highest CR rate.

我们的研究结果显示，抗CD19嵌合抗原受体T细胞疗法实现了最高的完全缓解率。

Additionally, bispecific antibodies, anti-CD19 ADCs/mAbs, and the combination of lenalidomide with obinutuzumab or rituximab also exhibited excellent efficacy.

此外，双特异性抗体、抗CD19抗体药物偶联物/单克隆抗体以及来那度胺与奥布替尼或利妥昔单抗的联合疗法也显示出卓越的疗效。

Notably, lenalidomide plus obinutuzumab showed superior efficacy compared with R2.

值得注意的是，雷那度胺联合奥布替尼显示出比R2更好的疗效。